<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC3611901/results/search/drugs/results.xml">
  <result pre="3611901 JPN-7-171 doi: 10.4103/1817-1745.106470 : Original Article Effective dose of" exact="topiramate" post="in pediatric migraine prophylaxis Abbaskhanian Ali Sadeghi Hamid Reza"/>
  <result pre="was planned and performed to evaluate the efficacy of low-dose" exact="topiramate" post="in pediatric migraine prophylaxis. Materials and Methods: A prospective"/>
  <result pre="were randomly divided into two treatment groups – treated by" exact="topiramate" post="&amp;lt; 2 mg/kg/day and &amp;gt; 2 mg/kg/day. All the"/>
  <result pre="the study for the clinical response. Results: The patients receiving" exact="topiramate" post="&amp;lt; 2 mg/kg/day (mean dose of 1.2 ± 0.7"/>
  <result pre="(±2.1) to 2.2 (±1.3) h. In the patients treated with" exact="topiramate" post="&amp;gt; 2 mg/kg/day (mean dose of 2.4 ± 0.5"/>
  <result pre="( P &amp;gt; 0.05). The most common side effects of" exact="topiramate" post="were paresthesias (five patients), anorexia (four patients), drowsiness (four"/>
  <result pre="Conclusion: The results of this study demonstrated that low-dose of" exact="topiramate" post="(&amp;lt;2 mg/kg/day) is effective, well-tolerated, safe, and suggested as"/>
  <result pre="an alternative prophylactic treatment for pediatric migraine. Pediatric migraine prophylaxis" exact="topiramate" post="Introduction Migraine is a common neurological disorder in childhood"/>
  <result pre="Limited data is available for the efficacy and safety of" exact="topiramate" post="in the pediatric population.[ 5] The exact mechanism of"/>
  <result pre="topiramate in the pediatric population.[ 5] The exact mechanism of" exact="topiramate" post="is unknown.[ 6] It is proposed that epilepsy and"/>
  <result pre="8] Few uncontrolled studies done to evaluate the efficacy of" exact="topiramate" post="in migraine prophylaxis especially in refractory causes confirmed that"/>
  <result pre="to support the effectiveness, tolerability, and adequate dosage of pediatric" exact="topiramate" post="are not well-reported. The present study was planned and"/>
  <result pre="was planned and performed to evaluate the efficacy of low-dose" exact="topiramate" post="in pediatric migraine prophylaxis. Materials and Methods The study"/>
  <result pre="children (between 5 and 15 years of age) treated with" exact="topiramate" post="for prevention of migraine headaches, at a pediatric neurology"/>
  <result pre="Neuroimaging studies indicative of a focal neurological lesion Contraindications for" exact="topiramate" post="(e.g., glaucoma, renal stone) Patients with known case of"/>
  <result pre="epilepsy. After simple randomized dividing the patients into two groups," exact="topiramate" post="was started at a dose of greater or lower"/>
  <result pre="based on the Visual Analog Scale (VAS). The response to" exact="topiramate" post="treatment was recorded according to the patients and parents′"/>
  <result pre="monthly headache frequency at the beginning of the study with" exact="topiramate" post="in two groups receiving &amp;gt; 2 mg/kg/day and &amp;lt;"/>
  <result pre="8 weeks of treatment The most common side effects of" exact="topiramate" post="were paresthesias (five patients), anorexia (four patients), and drowsiness"/>
  <result pre="study was designed and performed to compare different dosage of" exact="topiramate" post="in pediatric migraine prophylaxis. In our study, the mean"/>
  <result pre="prophylaxis. In our study, the mean dose in patients receiving" exact="topiramate" post="(&amp;lt;2 mg/kg/day) was 1.2 ± 0.7 mg/kg/day. (Range: 0.5-2"/>
  <result pre="group receiving more than 2 mg/kg/day. The mean dose of" exact="topiramate" post="used in several studies varied from 1.7 ± 1"/>
  <result pre="9 20] However, Winner et al.[ 20] suggested that possibly" exact="topiramate" post="at dose of 50 mg/day, administered prophylactically, may reduce"/>
  <result pre="Lewis et al.[ 21] evaluated the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects aged 12-17 years."/>
  <result pre="prevention in pediatric subjects aged 12-17 years. They found that" exact="topiramate" post="at 100 mg/day, but not 50 mg/day, resulted in"/>
  <result pre="Campistol et al.[ 22] presented that effective mean dose of" exact="topiramate" post="in pediatric migraine prophylaxis is 3.5 ± 1.7 mg/kg/day."/>
  <result pre="topiramate. In this report 62% of families reported that low-dose" exact="topiramate" post="(average dose of 30 mg/day) was successful in reducing"/>
  <result pre="episodes. Campistol et al.[ 22] presented 24 children treated with" exact="topiramate" post="for 4 months. And recorded a reduction in migraine"/>
  <result pre="side effects. Another study, evaluating the safety, and tolerability of" exact="topiramate" post="show that the most common side effects were paresthesia,"/>
  <result pre="tolerability, optimal dose, length of treatment, and long-term effects of" exact="topiramate" post="in this population. In conclusion, the results of this"/>
  <result pre="conclusion, the results of this study demonstrated that low-dose of" exact="topiramate" post="(&amp;lt;2 mg/kg/day) is effective, well-tolerated, safe, and suggested as"/>
  <result pre="2005 11 373 86 16061523 8 Faught E Efficacy of" exact="topiramate" post="as adjunctive therapy in refractory partial seizures: United States"/>
  <result pre="Khurana DS Yum S et al. Efficacy and tolerability of" exact="topiramate" post="in pediatric migraine Pediatr Neurol 2009 41 167 70"/>
  <result pre="Yum S Hardison HH et al. Efficacy and tolerability of" exact="topiramate" post="in children younger than 2 years old J Child"/>
  <result pre="19 Von Seggern RL Mannix LK Adelman JU Efficacy of" exact="topiramate" post="in migraine prophylaxis: A retrospective chart analysis Headache 2002"/>
  <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12-17 years of"/>
  <result pre="15832623 23 Borzy JC Koch TK Schimschock JR Effectiveness of" exact="topiramate" post="in the treatment of pediatric chronic daily headache Pediatr"/>
 </snippets>
</snippetsTree>
